Clinical Trials Directory

Trials / Completed

CompletedNCT02501382

Modulation of Biomarkers in Patients With Flesh-eating Bacterial Infections After With Hyperbaric Oxygen Treatment

Biomarkers in Necrotizing Soft Tissue Infections - Effects of Hyperbaric Oxygen Treatment on the Immune Response

Status
Completed
Phase
Study type
Observational
Enrollment
65 (actual)
Sponsor
Ole Hyldegaard · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to investigate the effects of hyperic oxygen treatment on the immune response in patients with necrotizing soft tissue infections

Detailed description

Necrotizing soft tissue infections (NSTI) is a complex, multi-factorial disease and the bacteria show a diverse microbial etiology. The exentisive inflammatory response caused by these bacteria is thought to be a main course of death. In Denmark, most NSTI patients are treated with hyperic oxygen therapy (HBOT). However, the effects of HBOT have never been investigated in NSTI patients. Location: Copenhagen University Hospital, Rigshospitalet, Denmark. Design: Observational cohort study. Cohort: NSTI patients in Denmark treated with HBOT. Biomarkers: Cytokines, acute-phase proteins, vasoactive biomarkers and other inflammatory biomarkers. Sample size calculation: The investigators expect a mean IL-6 concentration before HBOT of 3500 pg/ml (standard deviation 1500 pg/ml) and consider a reduction of 800 pg/ml to be clinically relevant. With an alpha = 0.05 and a power of 80%, 112 patients will be required. Data: The Danish Data Protection Agency has approved the processing of personal data for the NSTI patients (J. no. 30-0900). Ethics: The trial will adhere to the Helsinki Declaration and the Danish law. The National Ethics Committee and the Regional Scientific Ethics Committee of Copenhagen have approved the study (CVK-1211709 and H-2-2014-071). Analysis: Biomarker analyses will be performed once the recruitment of patients has ended.

Conditions

Timeline

Start date
2013-02-01
Primary completion
2015-12-01
Completion
2015-12-01
First posted
2015-07-17
Last updated
2019-06-24

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT02501382. Inclusion in this directory is not an endorsement.